Chugai Pharma traded at 3,664.00 this Thursday July 7th, increasing 40.00 or 1.10 percent since the previous trading session. Looking back, over the last four weeks, Chugai Pharma gained 0.94 percent. Over the last 12 months, its price fell by 13.07 percent. Looking ahead, we forecast Chugai Pharma to be priced at 3,358.86 by the end of this quarter and at 3,030.59 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
3,664.00
Daily Change
1.10%
Yearly
-13.07%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
M3 Inc 4,246.00 -18.00 -0.42% -45.26%
Kyowa Hakko Kirin 3,180.00 65.00 2.09% -20.99%
Takeda 3,932.00 70.00 1.81% 7.73%
Astellas Pharma 2,144.00 17.50 0.82% 14.93%
Sumitomo Dainippon 1,108.00 7.00 0.64% -49.89%
Shionogi 7,010.00 157.00 2.29% 21.39%
Chugai Pharma 3,664.00 40.00 1.10% -13.07%
Eisai 6,153.00 -14.00 -0.23% -41.29%
Terumo 4,214.00 115.00 2.81% -5.24%
Daiichi Sankyo 3,521.00 46.00 1.32% 55.04%
Otsuka Holdings 5,000.00 65.00 1.32% 16.31%

Indexes Price Day Year
JP225 26491 382.88 1.47% -5.79%

Chugai Pharma
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.